# Pathway Partners

> Pathway Partners is a VC fund in Gangneung backing Medical, Health Care and Biotechnology. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Gangneung, South Korea
- Total investments: 7
- Last investment: Feb 2026
- Lead investor: 29%
- Last updated: Aug 2026
- Website: https://pathwaygroup.co.kr/

Pathway Partners is a venture capital firm that focuses on investing in the technology industries.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 29% |
| Health Care | 2 | 29% |
| Biotechnology | 2 | 29% |
| Artificial Intelligence | 2 | 29% |
| Wellness | 1 | 14% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 43% |
| Series B | 2 | 29% |
| Seed | 1 | 14% |
| Post-IPO Debt | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Galux | Galux provides molecular design technology focusing on discovering and developing novel drugs for incurable and rare diseases using its AI-based drug design platform technologies. | $29M | Series B | Feb 09, 2026 |  |
| Imeditech | Imeditech develops, manufactures, and sells medical devices. | $1M | Series A | Feb 04, 2026 |  |
| Eul Biosciences | Eul Bioscience is a life science firm that focuses on stem cell exosomes. Eul Bioscience specializes in creating regenerative aesthetic cosmetics and wound dressings that utilize stem cells and exosomes derived from them. Exosomes have recently gained prominence in areas such as cosmetics and skin boosters, serving as vehicles for substancessecreted by cells in the body to convey information. Specifically, stem cell exosomes transport substances that contribute to anti-aging, tissue regeneration, and the regulation of inflammation and immunity, which are released into adjacent cells. Eul Bioscience operates a hospital platform under the 'Eeul' brand, encompassing plastic surgery, orthopedics, dentistry, ophthalmology, and veterinary clinics. With this foundation, the company has achieved vertical integration of its entire value chain, from the procurement of stem cells to the production of exosomes. This strategy is marked by the careful selection of high-quality stem cells and the guarantee of efficiency during the purchasing process. Eul Bioscience stands out as the sole company in Korea with such a comprehensive value chain. Another notable advantage is its proprietary culture technology, which significantly enhances the volume of exosome secretion. Furthermore, the company is adept at developing customized products that meet the specific requirements of hospitals and clinics. | $11.3M | Series A | Sep 25, 2024 |  |
| Galux | Galux provides molecular design technology focusing on discovering and developing novel drugs for incurable and rare diseases using its AI-based drug design platform technologies. | $3.1M | Series A | Jul 12, 2022 |  |
| Medifab | Medifab is a bio-healthcare center that offers 3D system testing, measurement analysis, and OEM service. | $16.7M | Series B |  |  |
| Vuno | Vuno offers artificial intelligence-based medical solutions for doctors and patients that provides a platform and consulting services for medical data analysis.Vuno develops automatic algorithm against various problems that occurs in medical sites as well as it develops diagnostic and quantification assisting software. The clients of the companyare Asan Medical Center and HYUNDAI. The company offers VunoMed that provides different forms of data analyzation for medical videos, ECGs, brain waves, and EMR data.Vuno is located in South Korea and the company was founded in 2014 by Yeha Lee, Kyu-Hwan Jung, and Dannis Kim. | $7M | Post-IPO Debt |  |  |
| iamHERE | iamHERE is a lifestyle brand offering products that promote mindfulness and presence, including apparel, accessories, and tools designed to help individuals stay grounded and focused on the present moment. Their designs support a mindful lifestyle emphasizing simplicity and intentionality. |  | Seed |  |  |

7 of 7 investments shown.

## Co-investors
- [Dayli Partners](https://shizune.co/investors/profile/dayli-partners) — VC Fund, 2 deals together
- [Mirae Asset Venture Investment](https://shizune.co/investors/profile/mirae-asset-venture-investment) — VC Fund, 2 deals together
- [Snickpick Investment](https://shizune.co/investors/profile/snickpick-investment) — VC Fund, 2 deals together
- [D·CAMP](https://shizune.co/investors/profile/banks-foundation-for-young-entrepreneurs) — VC Fund, 1 deal together
- [BNK Securities](https://shizune.co/investors/profile/bnk-securities-7af0) — VC Fund, 1 deal together
- [Hanwha Investment & Securities](https://shizune.co/investors/profile/hanwha-investment-securities) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Pathway Partners invest in?

Pathway Partners invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Pathway Partners last invest?

The most recent investment recorded for Pathway Partners closed in Feb 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co